US companies collaborate on wound management:
This article was originally published in Clinica
US wound management companies FibroGen and ZymoGenetics have agreed to work together on a new range of tissue sealant products. ZymoGenetics, of Seattle, Washington, will combine its recombinant thrombin with the recombinant type III collagen developed by FibroGen, of South San Francisco.
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.